Overview

A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump

Status:
Completed
Trial end date:
2017-06-19
Target enrollment:
Participant gender:
Summary
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability will be documented. The study will last about 4 to 11 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc